Efficiency Perspectives on Adaptive Designs in Stroke Clinical Trials
Authors:
- 1 October 2011
- journal article
- review article
- Published by Wolters Kluwer Health in Stroke
- Vol. 42 (10) , 2990-2994
Abstract
An adaptive design allows the modifications of various features, such as sample size and treatment assignments, in a clinical study based on the analysis of interim data. The goal is to enhance statistical efficiency by maximizing relevant information obtained from the clinical data. The promise of efficiency, however, comes with a cost, per se, that is seldom made explicit in the literature. This article reviews some commonly used adaptive strategies in early-phase stroke trials and discusses their associated costs. Specifically, we illustrate the trade-offs in several clinical contexts, including dose-finding in the Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART), futility analyses and internal pilot in Phase 2 proof-of-concept trials, and sample size considerations in an imaging-based dose-selection trial. Through these illustrations, we demonstrate the potential tension between the perspectives of an individual investigator and that of the broader community of stakeholders. This understanding is critical to appreciate the limitations, as well as the full promise, of adaptive designs, so that investigators can deploy an appropriate statistical design—be it adaptive or not—in a clinical study.Keywords
This publication has 26 references indexed in Scilit:
- High-Dose Lovastatin for Acute Ischemic Stroke: Results of the Phase I Dose Escalation Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART)Cerebrovascular Diseases, 2009
- Adaptive designs for confirmatory clinical trialsStatistics in Medicine, 2009
- The Neuroprotection with Statin Therapy for Acute Recovery Trial (Neustart): An Adaptive Design Phase I Dose-Escalation Study of High-Dose Lovastatin in Acute Ischemic StrokeInternational Journal of Stroke, 2008
- Proof-of-Principle Phase II MRI Studies in StrokeStroke, 2006
- New Pathways for Evaluating Potential Acute Stroke TherapiesInternational Journal of Stroke, 2006
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- The Randomized Play-the-Winner Rule in Medical TrialsJournal of the American Statistical Association, 1978
- A Stochastic Approximation MethodThe Annals of Mathematical Statistics, 1951
- ON THE LIKELIHOOD THAT ONE UNKNOWN PROBABILITY EXCEEDS ANOTHER IN VIEW OF THE EVIDENCE OF TWO SAMPLESBiometrika, 1933